441 related articles for article (PubMed ID: 23510123)
21. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
Unuvar A; Warrier I; Lusher JM
Haemophilia; 2000 May; 6(3):150-7. PubMed ID: 10792472
[TBL] [Abstract][Full Text] [Related]
22. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
23. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
24. New predictive approaches for ITI treatment.
Minno GD; Santagostino E; Pratt K; Königs C
Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
[TBL] [Abstract][Full Text] [Related]
25. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
26. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
[TBL] [Abstract][Full Text] [Related]
27. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
28. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
30. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
31. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).
Rocino A; Cortesi PA; Scalone L; Mantovani LG; Crea R; Gringeri A; ;
Haemophilia; 2016 Jan; 22(1):96-102. PubMed ID: 26278414
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
33. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
[TBL] [Abstract][Full Text] [Related]
34. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
35. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
[TBL] [Abstract][Full Text] [Related]
36. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.
Jiménez-Yuste V; Oldenburg J; Rangarajan S; Peiró-Jordán R; Santagostino E
Haemophilia; 2016 Nov; 22(6):859-865. PubMed ID: 27329267
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
40. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
Benson G; Auerswald G; Elezović I; Lambert T; Ljung R; Morfini M; Remor E; Salek SZ
Eur J Haematol; 2012 May; 88(5):371-9. PubMed ID: 22260405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
